

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-18. (Canceled)

19. (Previously Presented) An immunogenic composition according to claim 61, wherein the immunostimulant is an adjuvant.

20.-21. (Canceled)

22. (Previously Presented) A method for stimulating an immune response in a patient, comprising administering to a patient an effective amount of an immunogenic composition according to claim 61.

23.-60. (Canceled)

61. (Previously Presented) An immunogenic composition comprising an immunostimulant which induces a predominantly Th1-type immune response and a polypeptide, wherein the polypeptide comprises at least amino acid residues 367-375 of SEQ ID NO: 113 and stimulates a human cytotoxic T lymphocyte response specific for SEQ ID NO: 113.

62. (Canceled)

63. (Previously Presented) An immunogenic composition according to claim 61, wherein the immunostimulant is selected from the group consisting of: monophosphoryl lipid A; 3-de-O-acylated monophosphoryl lipid A; and saponins.

64. (Currently amended) An immunogenic composition comprising an immunostimulant which induces a predominantly Th1-type immune response and an antigen-presenting cell that expresses a polypeptide, wherein the polypeptide comprises the T-cell epitope of amino acid residues 367-375 of SEQ ID NO: 113; and wherein the polypeptide stimulates a human cytotoxic T lymphocyte response specific for SEQ ID NO: 113.

65. (Previously Presented) A method for stimulating an immune response in a patient, comprising administering a composition according to claim 64.